Between 1985 and 2010, 5,957 patients were treated with RP at a single referral center. The rates of overall mortality, cancer-specific mortality (CSM) and of biochemical recurrence (BCR) according to clinical and pathological patient characteristics were determined.
Among 5,957 patients treated with RP, 728 (12.2%) had follow-up > 10 years. These patients were treated between 1986 and 2000. Mean and median follow-up were 152 and 144 months, respectively. At RP, mean PSA was 17.4. Pathological Gleason score was 2-6, 7 and 8-10 in 56.3, 22.8 and 14.9% of patients, respectively. Pathological stage showed organ confined disease, extracapsular extension, seminal vesicle invasion and lymph node involvement in 57.2, 13.3, 20.8 and 20.4% of patients, respectively. Positive surgical margins were found in 11.5% of patients. The 10- and 15-year BCR-free survival rates were 61 and 52%, respectively. The 10- and 15-year overall survival rates were 77 and 65% respectively. The 10- and 15-year freedom from CSM rates were 89 and 85%, respectively. Among 337 patients who had recurrence, 149 (44.2%) and 46 (13.6%) developed BCR beyond 5 and 10 years of follow-up. Of 85 patients who died of prostate cancer, 53 (62.3%) and 12 (14.1%) died beyond 5 and 10 years of follow-up, respectively. Surprisingly, 11%, 14% and 11% of low-, intermediate- and high-risk patients entering the 10-year interval respectively experienced BCR beyond the 10-year landmark.
Presented by Nazareno Suardi, MD, FEBU, et al. at the 26th Annual European Association of Urology (EAU) Congress - March 18 - 21, 2011 - Austria Centre Vienna, Vienna, Austria
View EAU 2011 Annual Meeting Coverage
